Trial Profile
A RANDOMIZED PHASE II STUDY OF TAXOTERE, OXALIPLATIN, CAPECITABINE (TOX) OR EPIDOXORUBICIN, OXALIPLATIN AND CAPECITABINE (EOX) IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2012
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Epirubicin (Primary) ; Capecitabine; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- 29 Jul 2011 New trial record